{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:07:19Z","timestamp":1790856439381,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Breast cancer (BC) is the most prevalent malignant neoplasm among women and is the fifth most common cause of cancer-associated death worldwide. Acquired chemoresistance driven by genetic and epigenetic alterations is a significant clinical challenge in treating BC. However, the mechanism of BC cell resistance to adriamycin (ADR) remains to be elucidated. In this study, we identified the methyltransferase-like 3\/microRNA-221-3p\/homeodomain-interacting protein kinase 2\/Che-1 (METTL3\/miR-221-3p\/HIPK2\/Che-1) axis as a novel signaling event that may be responsible for resistance of BC cells to ADR. A dual-luciferase reporter gene assay was employed to test the presence of miR-221-3p binding sites in the 3\u2032UTR of HIPK2. Drug resistance was evaluated by immunoblotting multidrug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP). Cultured ADR-resistant MCF-7 cells were assayed for their half maximal inhibitory concentration (IC50) values and apoptosis using an MTT assay and Annexin V-FITC\/PI-labeled flow cytometry, and the cells were then xenografted into nude mice. METTL3 knockdown was shown to reduce the expression of miR-221-3p by reducing pri-miR-221-3p m6A mRNA methylation, thereby reducing the IC50 value of ADR-resistant MCF-7 cells, reducing the expression of MDR1 and BCRP, and inducing apoptosis. Mechanistically, miR-221-3p was demonstrated to negatively regulate HIPK2 and upregulate its direct target Che-1, thus leading to enhanced drug resistance in ADR-resistant MCF-7 cells. In vitro results were reproduced in nude mice xenografted with ADR-resistant MCF-7 cells. Our work elucidates an epigenetic mechanism of acquired chemoresistance in BC, in support of the METTL3\/miR-221-3p\/HIPK2\/Che-1 axis as a therapeutic target for the improvement of chemotherapy.<\/jats:p>","DOI":"10.1038\/s12276-020-00510-w","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T07:09:58Z","timestamp":1610089798000},"page":"91-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner"],"prefix":"10.1038","volume":"53","author":[{"given":"Xiaoping","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolv","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"510_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"Cancer J. Clin."},{"key":"510_CR2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2174\/187152012803529646","volume":"12","author":"J Prados","year":"2012","unstructured":"Prados, J. et al. Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anticancer Agents Med. Chem. 12, 1058\u20131070 (2012).","journal-title":"Anticancer Agents Med. Chem."},{"key":"510_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CAD.0000000000000572","volume":"29","author":"C Chen","year":"2018","unstructured":"Chen, C. et al. Autophagy and doxorubicin resistance in cancer. Anticancer Drugs 29, 1\u20139 (2018).","journal-title":"Anticancer Drugs"},{"key":"510_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2018.04.018","volume":"292","author":"S Gu","year":"2018","unstructured":"Gu, S., Sun, D., Dai, H. & Zhang, Z. N(6)-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells. Toxicol. Lett. 292, 1\u201311 (2018).","journal-title":"Toxicol. Lett."},{"key":"510_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/978-3-030-20301-6_18","volume":"1152","author":"N Naser Al Deen","year":"2019","unstructured":"Naser Al Deen, N., Nassar, F., Nasr, R. & Talhouk, R. Cross-roads to drug resistance and metastasis in breast cancer: miRNAs regulatory function and biomarker capability. Adv. Exp. Med. Biol. 1152, 335\u2013364 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"510_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-019-0830-6","volume":"12","author":"D Jin","year":"2019","unstructured":"Jin, D. et al. m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J. Hematol. Oncol. 12, 135 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"510_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J Han","year":"2019","unstructured":"Han, J. et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner. Mol. Cancer 18, 110 (2019).","journal-title":"Mol. Cancer"},{"key":"510_CR8","doi-asserted-by":"publisher","first-page":"144076","DOI":"10.1016\/j.gene.2019.144076","volume":"722","author":"H Wang","year":"2020","unstructured":"Wang, H., Xu, B. & Shi, J. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2. Gene 722, 144076 (2020).","journal-title":"Gene"},{"key":"510_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1159\/000334552","volume":"34","author":"R Zhao","year":"2011","unstructured":"Zhao, R. et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 34, 675\u2013680 (2011).","journal-title":"Onkologie"},{"key":"510_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2174\/2211536607666180525102330","volume":"7","author":"A Conte","year":"2018","unstructured":"Conte, A. & Pierantoni, G. M. Update on the regulation of HIPK1, HIPK2 and HIPK3 protein kinases by microRNAs. Microrna 7, 178\u2013186 (2018).","journal-title":"Microrna"},{"key":"510_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/sj.cdd.4402284","volume":"15","author":"T Bruno","year":"2008","unstructured":"Bruno, T. et al. Che-1 activates XIAP expression in response to DNA damage. Cell Death Differ. 15, 515\u2013520 (2008).","journal-title":"Cell Death Differ."},{"key":"510_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.381","volume":"5","author":"F De Nicola","year":"2014","unstructured":"De Nicola, F. et al. HIPK2 sustains apoptotic response by phosphorylating Che-1\/AATF and promoting its degradation. Cell Death Dis. 5, e1414 (2014).","journal-title":"Cell Death Dis."},{"key":"510_CR13","first-page":"287","volume":"35","author":"AA Kovalev","year":"2013","unstructured":"Kovalev, A. A., Tsvetaeva, D. A. & Grudinskaja, T. V. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp. Oncol. 35, 287\u2013290 (2013).","journal-title":"Exp. Oncol."},{"key":"510_CR14","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1158\/0008-5472.CAN-18-3544","volume":"79","author":"J Mukohyama","year":"2019","unstructured":"Mukohyama, J. et al. miR-221 targets QKI to enhance the tumorigenic capacity of human colorectal cancer stem cells. Cancer Res. 79, 5151\u20135158 (2019).","journal-title":"Cancer Res."},{"key":"510_CR15","first-page":"704","volume":"66","author":"J Wang","year":"2011","unstructured":"Wang, J. et al. Effects of adenovirus vectors mediated human lactoferrin cDNA on mice bearing EMT6 breast carcinoma. Pharmazie 66, 704\u2013709 (2011).","journal-title":"Pharmazie"},{"key":"510_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbrc.2018.08.043","volume":"504","author":"XN Wang","year":"2018","unstructured":"Wang, X. N., Wang, K. Y., Zhang, X. S., Yang, C. & Li, X. Y. 4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2\/p53 pathway. Biochem. Biophys. Res. Commun. 504, 812\u2013819 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"510_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clbc.2016.05.012","volume":"16","author":"Y Tang","year":"2016","unstructured":"Tang, Y., Wang, Y., Kiani, M. F. & Wang, B. Classification, treatment strategy, and associated drug resistance in breast cancer. Clin. Breast Cancer 16, 335\u2013343 (2016).","journal-title":"Clin. Breast Cancer"},{"key":"510_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-981-10-6020-5_4","volume":"1026","author":"KH Chun","year":"2017","unstructured":"Chun, K. H., Park, J. H. & Fan, S. Predicting and overcoming chemotherapeutic resistance in breast cancer. Adv. Exp. Med. Biol. 1026, 59\u2013104 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"510_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ebiom.2019.07.068","volume":"47","author":"H Jin","year":"2019","unstructured":"Jin, H. et al. N(6)-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer. EBioMedicine 47, 195\u2013207 (2019).","journal-title":"EBioMedicine"},{"key":"510_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.gene.2014.11.036","volume":"555","author":"S Ergun","year":"2015","unstructured":"Ergun, S. et al. The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines. Gene 555, 377\u2013381 (2015).","journal-title":"Gene"},{"key":"510_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.gene.2015.08.004","volume":"574","author":"S Eissa","year":"2015","unstructured":"Eissa, S., Matboli, M., Sharawy, A. & El-Sharkawi, F. Prognostic and biological significance of microRNA-221 in breast cancer. Gene 574, 163\u2013167 (2015).","journal-title":"Gene"},{"key":"510_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7754\/Clin.Lab.2017.170821","volume":"64","author":"A Abak","year":"2018","unstructured":"Abak, A. et al. Analysis of miRNA-221 expression level in tumors and marginal biopsies from patients with breast cancer (cross-sectional observational study). Clin. Lab 64, 169\u2013175 (2018).","journal-title":"Clin. Lab"},{"key":"510_CR23","doi-asserted-by":"crossref","unstructured":"Zong, Y. et al. miR-221\/222 promote tumor growth and suppress apoptosis by targeting lncRNA GAS5 in breast cancer. Biosci. Rep. 39, (2019).","DOI":"10.1042\/BSR20181859"},{"key":"510_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.biopha.2016.01.026","volume":"78","author":"M Hemmatzadeh","year":"2016","unstructured":"Hemmatzadeh, M., Mohammadi, H., Jadidi-Niaragh, F., Asghari, F. & Yousefi, M. The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed. Pharmacother. 78, 129\u2013139 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"510_CR25","doi-asserted-by":"publisher","first-page":"101042831770163","DOI":"10.1177\/1010428317701636","volume":"39","author":"T Ning","year":"2017","unstructured":"Ning, T. et al. miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer. Tumour Biol. 39, 1010428317701636 (2017).","journal-title":"Tumour Biol."},{"key":"510_CR26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s13277-011-0219-9","volume":"32","author":"Q Yao","year":"2011","unstructured":"Yao, Q. et al. The significance of expression of autophagy-related gene Beclin, Bcl-2, and Bax in breast cancer tissues. Tumour Biol. 32, 1163\u20131171 (2011).","journal-title":"Tumour Biol."},{"key":"510_CR27","doi-asserted-by":"publisher","first-page":"7122","DOI":"10.3390\/molecules19067122","volume":"19","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. miR-221\/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules 19, 7122\u20137137 (2014).","journal-title":"Molecules"},{"key":"510_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/cbin.11071","volume":"43","author":"D Yi","year":"2019","unstructured":"Yi, D., Xu, L., Wang, R., Lu, X. & Sang, J. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol. Int. 43, 12\u201321 (2019).","journal-title":"Cell Biol. Int."},{"key":"510_CR29","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.6309","volume":"7","author":"Z Rehman","year":"2019","unstructured":"Rehman, Z., Fahim, A., Bhatti, A., Sadia, H. & John, P. Co-expression of HIF-1alpha, MDR1 and LAPTM4B in peripheral blood of solid tumors. PeerJ 7, e6309 (2019).","journal-title":"PeerJ"},{"key":"510_CR30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ygyno.2015.11.034","volume":"141","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. miR-302a\/b\/c\/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol. Oncol. 141, 592\u2013601 (2016).","journal-title":"Gynecol. Oncol."},{"key":"510_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4161\/cbt.13.4.18694","volume":"13","author":"C Nodale","year":"2012","unstructured":"Nodale, C. et al. HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. Cancer Biol. Ther. 13, 198\u2013205 (2012).","journal-title":"Cancer Biol. Ther."},{"key":"510_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fgene.2015.00141","volume":"6","author":"S Iezzi","year":"2015","unstructured":"Iezzi, S. & Fanciulli, M. Discovering Che-1\/AATF: a new attractive target for cancer therapy. Front. Genet. 6, 141 (2015).","journal-title":"Front. Genet."},{"key":"510_CR33","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s10529-013-1257-8","volume":"35","author":"M Sharma","year":"2013","unstructured":"Sharma, M. Apoptosis-antagonizing transcription factor (AATF) gene silencing: role in induction of apoptosis and down-regulation of estrogen receptor in breast cancer cells. Biotechnol. Lett. 35, 1561\u20131570 (2013).","journal-title":"Biotechnol. Lett."},{"key":"510_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.abb.2018.05.018","volume":"651","author":"H Zeng","year":"2018","unstructured":"Zeng, H. et al. microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2. Arch. Biochem. Biophys. 651, 52\u201360 (2018).","journal-title":"Arch. Biochem. Biophys."},{"key":"510_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.gene.2016.10.016","volume":"596","author":"H Shen","year":"2017","unstructured":"Shen, H. et al. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN\/Akt\/FOXO1 pathway. Gene 596, 110\u2013118 (2017).","journal-title":"Gene"},{"key":"510_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bcp.2018.03.022","volume":"152","author":"W Kai","year":"2018","unstructured":"Kai, W. et al. Natural product toosendanin reverses the resistance of human breast cancer cells to adriamycin as a novel PI3K inhibitor. Biochem. Pharm. 152, 153\u2013164 (2018).","journal-title":"Biochem. Pharm."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s12276-020-00510-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s12276-020-00510-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s12276-020-00510-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:11:21Z","timestamp":1684617081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-00510-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1038\/s12276-020-00510-w","relation":{},"ISSN":["1226-3613","2092-6413"],"issn-type":[{"value":"1226-3613","type":"print"},{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}